title: Overcoming resistance to MAPK pathway inhibitors.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Davies
authors.forename: Scott
authors.initials: S
authors.lastname: Kopetz
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology*; D006801:Humans; D008545:Melanoma / Q000188:drug therapy*; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors*; D058990:Molecular Targeted Therapy / Q000379:methods*; D044767:Ubiquitin-Protein Ligases / Q000378:metabolism*
chemical_list: C120227:2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide; C517975:AZD 6244; D000970:Antineoplastic Agents; D001549:Benzamides; D001562:Benzimidazoles; C471641:SMURF2 protein, human; D044767:Ubiquitin-Protein Ligases; D020928:Mitogen-Activated Protein Kinases